Simon Read, Mariana Oncology CEO

Mar­i­ana On­col­o­gy, a ra­dio­phar­ma start­up found­ed by top-tier VCs, nabs $175M Se­ries B

De­spite ad­vances in de­vel­op­ing ra­dio­phar­ma­ceu­ti­cals, man­u­fac­tur­ing such drugs re­mains a chal­lenge. One start­up’s plan to tack­le the is­sue is be­gin­ning to round in­to form and, si­mul­ta­ne­ous­ly, it’s re­ceiv­ing a hearty, cash-rich en­dorse­ment.

Mar­i­ana On­col­o­gy, a biotech in­cu­bat­ed by three promi­nent life sci­ences VC firms, closed a $175 mil­lion Se­ries B round Thurs­day morn­ing, as its first pipeline pro­gram pre­pares to be­gin hu­man test­ing some­time next year. The start­up, found­ed as Curie Ther­a­peu­tics by At­las Ven­ture, RA Cap­i­tal Man­age­ment and Ac­cess Biotech­nol­o­gy, will fo­cus that drug can­di­date in small cell lung can­cer pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.